Form 4: Tarsus Pharmaceuticals Director Wendy L. Yarno Acquires Stock Options and Restricted Stock Units

Wendy L. Yarno, a director at Tarsus Pharmaceuticals, acquired stock options and restricted stock units (RSUs) as part of her compensation for serving as a non-employee director.

Summary

• On June 13, 2024, Wendy L. Yarno, a director of Tarsus Pharmaceuticals, acquired stock options and restricted stock units (RSUs).
• The stock options grant the right to buy 5,000 shares of common stock at an exercise price of $33.14 per share.
• These options vest in full on June 12, 2025, contingent upon continuous service as a non-employee director.
• Additionally, Yarno received 3,350 RSUs, each representing a contingent right to receive one share of Tarsus Pharmaceuticals' common stock.
• These RSUs also vest in full on June 13, 2025, subject to continuous service as a non-employee director.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice for a director, indicating a stable and expected aspect of the company's governance. The sentiment is neutral to slightly positive as it aligns director interests with shareholders.

Positives

• The acquisition of stock options and RSUs aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Industry Context

This type of equity compensation is standard practice for directors of publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Granting stock options and RSUs to non-employee directors is a common practice among publicly traded pharmaceutical companies.
• Companies like Alnylam Pharmaceuticals and BioMarin Pharmaceutical also utilize similar equity compensation packages for their board members.
• The vesting schedules, typically one year, are also in line with industry norms.

Stakeholder Impact

• The equity grants align the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates